BALAXI PHARMACEUTICALS profit and loss

·UnclassifiedChart ›

Latest FY26

Revenue: ₹270cr−7.7% on FY25
EBITDA: ₹8.5cr−77.1% on FY25
Net profit: ₹1.4cr−94.3% on FY25
EPS: ₹0.26−94.3% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	280	270	293	241	336	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	3.6	2.8	−3.7	−2.6	2.6
	284	273	289	239	339
	154	151	166	129	202
	41.1	38.2	34.7	27.4	29.0
	3.6	3.9	2.9	1.7	0.5
	2.5	2.2	1.9	2.1	1.8
	75.4	72.6	54.9	38.5	48.5
	277	268	260	198	282
	9.0	8.5	37.2	46.7	56.5
	6.5	6.4	35.3	44.6	54.8
Profit
	6.5	5.3	28.7	40.3	56.9
	0.0	0.0	0.0	−38.3	0.0
	6.5	5.3	28.7	2.0	56.9
	3.5	3.4	3.7	4.5	9.9
	0.6	0.4	−0.1	−0.1	1.1
	4.1	3.9	3.6	4.4	11.0
	2.4	1.4	25.1	−2.4	46.0
	2.4	1.4	25.1	−2.4	46.0
	17.6	15.9	2.6	−4.9	5.8
	20.0	17.3	27.7	−7.3	51.7
	—	—	—	—	46.0
Per share
	₹0.45	₹0.26	₹4.54	−₹2.32	₹45.81
	₹0.45	₹0.26	₹4.54	−₹2.31	₹45.40
Other comprehensive income — detail
	17.6	15.9	2.6	—	—
	17.6	15.9	2.6	—	—
	—	—	—	4.9	—
	—	—	—	—	51.7
Per share — as-filed variants
	₹0.45	₹0.26	₹4.54	−₹2.32	₹45.81
	₹0.45	₹0.26	₹4.54	−₹2.31	₹45.40
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	126	119	127	113	134
	44.8%	44.2%	43.4%	46.7%	39.8%
Adjusted (ex-exceptional items) — derived
	6.5	5.3	28.7	40.3	56.9
	0.0	0.0	0.0	−38.3	0.0
	2.4	1.4	25.1	12.9	46.0
	₹0.45	₹0.26	₹4.54	₹12.57	₹45.81

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BALAXI₹19.71

BALAXI PHARMACEUTICALS LIMITED

· Unclassified

Annual Quarterly₹ CrorePeersPAR STEELCITY LATTEYS CROWN HECPROJECT HINDCON AIROLAM GROBTEAMcap ₹109 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	336.4	241.3	292.6	270.2	280.1
Other Income	2.6	-2.6	-3.7	2.8	3.6
Total Income	339.1	238.6	288.8	273.0	283.7
Expenses
+ Cost of Materials Consumed	202.4	128.7	165.7	150.9	154.5
+ Employee Benefit Expense	29.0	27.4	34.7	38.2	41.1
+ Finance Costs	0.5	1.7	2.9	3.9	3.6
+ Depreciation & Amortisation	1.8	2.1	1.9	2.2	2.5
+ Other Expenses	48.5	38.5	54.9	72.6	75.4
Total Expenses	282.1	198.3	260.2	267.7	277.2
EBITDA	56.5	46.7	37.2	8.5	9.0
EBIT	54.8	44.6	35.3	6.4	6.5
Profit
PBT before Exceptional Items	56.9	40.3	28.7	5.3	6.5
+ Exceptional Items	0.0	-38.3	0.0	0.0	0.0
Pretax Income	56.9	2.0	28.7	5.3	6.5
+ Current Tax	9.9	4.5	3.7	3.4	3.5
+ Deferred Tax	1.1	-0.1	-0.1	0.4	0.6
Tax Expense	11.0	4.4	3.6	3.9	4.1
Net Income	46.0	-2.4	25.1	1.4	2.4
+ Net Income — Continuing Ops	46.0	-2.4	25.1	1.4	2.4
+ Other Comprehensive Income	5.8	-4.9	2.6	15.9	17.6
Total Comprehensive Income	51.7	-7.3	27.7	17.3	20.0
Net Income to Common	46.0	—	—	—	—
Per Share
Basic EPS	45.81	-2.32	4.54	0.26	0.45
Diluted EPS	45.40	-2.31	4.54	0.26	0.45
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	2.6	15.9	17.6
+ Items NOT to be Reclassified to P&L	—	—	2.6	15.9	17.6
+ Tax on Items NOT to be Reclassified — alt tag	—	4.9	—	—	—
Comprehensive Income — Owners of Parent	51.7	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	45.81	-2.32	4.54	0.26	0.45
Diluted EPS — Continuing Operations	45.40	-2.31	4.54	0.26	0.45
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	134.0	112.6	126.9	119.3	125.6
Gross Margin %	39.83	46.67	43.36	44.16	44.85
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	56.9	40.3	28.7	5.3	6.5
− Exceptional Items (reconciliation)	0.0	-38.3	0.0	0.0	0.0
Net Income Adj (tax-effected)	46.0	12.9	25.1	1.4	2.4
EPS Adj	45.81	12.57	4.54	0.26	0.45
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	2.00	2.00	2.00
Paid Up Equity Capital	10.2	10.9	11.0	11.0	11.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.